Drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced that it has filed a new patent application with the United States Patent and Trademark Office for the use of its DehydraTECH™ technology to improve the speed and quantity of absorption of active pharmaceutical ingredients through the skin. This update comes on the heels of Lexaria’s recently detailed successful laboratory evaluation of DehydraTECH™ in the transdermal delivery of cannabidiol. Per company data, the platform demonstrated as much as a 225 percent increase in CBD permeability when compared to control formulations featuring leading commercial penetration enhancers, as well as a nearly 1,900 percent increase in CBD permeability when compared to a control formulation that was devoid of any commercial penetration enhancer. This new patent application includes protection for the delivery of all of the active ingredient classes identified in Lexaria’s other issued and pending patent applications, including cannabinoids, terpenes and terpenoids, NSAIDs, vitamins, nicotine and phosphodiesterase inhibitors.
To view the full press release, visit http://nnw.fm/W5cCY
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit www.LexariaBioscience.com
More from NetworkNewsBreaks
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
